Almirall (ALM.MC) — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

ALM.MC · Stock Price

EUR 12.10+2.30 (+23.47%)

Market Cap: $3.1B

Historical price data

Market Cap: $3.1BPipeline: 66 drugs (21 Phase 3)Patents: 5Founded: 1943Employees: 2000-5000HQ: Barcelona, Spain

Overview

Almirall is a publicly traded, revenue-generating pharmaceutical company with a singular strategic focus on becoming a global leader in medical dermatology. The company has successfully transformed from a broad-based pharma player into a specialized dermatology entity, leveraging deep internal R&D, strategic partnerships, and a direct commercial infrastructure. Its mission is to deliver innovative science to improve the lives of patients with skin conditions, supported by a growing portfolio of marketed products and a promising clinical pipeline.

Medical DermatologySkin Health

Technology Platform

An integrated dermatology ecosystem combining deep internal formulation and R&D expertise with a proactive external innovation model for in-licensing and strategic partnerships, all supported by a direct commercial infrastructure.

Pipeline

66

66 drugs in pipeline21 in Phase 3

Drug	Indication	Stage
Tildrakizumab	Plaque Psoriasis	Approved
Tiotropium + Aclidinium	Pulmonary Disease, Chronic Obstructive	Approved
Dimethyl fumarate (DMF) standard scheme + Dimethyl fumarate ...	Plaque Psoriasis	Approved
Pidotimod + Placebo	Recurrent Respiratory Tract Infections	Approved
Tirbanibulin (Klisyri®) 10 mg/g ointment + Diclofenac Sodium...	Keratosis, Actinic	Approved

Funding History

1

IPOUndisclosedUndisclosedJul 3, 2007

FDA Approved Drugs

9

KLISYRINDADec 14, 2020

SEYSARANDAOct 1, 2018

ACZONENDAFeb 24, 2016

Opportunities

The global launch of lebrikizumab in atopic dermatitis represents a multi-billion dollar market opportunity.

Further geographic and label expansion for recent launches like Klisyri and Wynzora, coupled with a promising early-stage pipeline targeting novel immunology pathways, provide multiple avenues for sustained growth.

Risk Factors

Key risks include regulatory or commercial setbacks for lebrikizumab, particularly in the critical US market, intense competition from larger pharma and innovative biotechs, and pipeline concentration given reliance on a limited number of key assets for near-term growth.

Competitive Landscape

Almirall competes with global pharma giants (AbbVie, J&J, Pfizer) in immunodermatology and specialized biotechs (Arcutis, MoonLake). Its competitive advantage lies in its pure-play dermatology focus, integrated European commercial platform, and agile partnership-driven pipeline strategy.